Deals & Cases

Homburger advised DKSH in its Acquisition of the Refarmed Group

On June 27, 2022, DKSH Holding Ltd (SIX: DKSH) announced the acquisition of Swiss Refarmed Group. Refarmed Group provides Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for generic drug manufacturers. This includes the sourcing of the ingredients as well as providing technical and regulatory support.

Headquartered in Switzerland, Refarmed’s team of pharmaceutical experts serves approximately 300 customers across Europe, Asia, and the Americas. Refarmed generates net sales of over CHF 60 m at sound profitability and return on capital.

Through the acquisition of Refarmed Group, DKSH Business Unit Performance Materials, the leading global distributor of innovative pharmaceutical ingredients synthesis and formulation with vast and constantly growing global geographic reach, obtains a uniquely positioned business which provides value-added products and services for customers in the pharma industry across Europe, Asia Pacific, and the Americas. DKSH Switzerland Ltd will acquire the business and will fully integrate Refarmed Group into its existing operations.

Homburger has advised DKSH in this transaction.

The Homburger team comprised partner Frank Gerhard, associates Anna Peter and Timo Hasler, junior associate Alexander Cochardt (all Corporate / M&A), as well as partner Reto Heuberger and associate Laetitia Fracheboud (both Tax).